Limits...
Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.

Li AQ, Zhou SL, Li M, Xu Y, Shui RH, Yu BH, Yang WT - PLoS ONE (2015)

Bottom Line: The prognostic significance of PR expression appeared more pronounced in patients under a high Ki-67 status than those under a low Ki-67 status.Based on these findings, we propose the use of a novel threshold of 20% to define PgR status.Nevertheless, the impact of this new criterion on patient management and clinical treatment requires additional study.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.

ABSTRACT

Purpose: A lack of progesterone receptor (PgR) expression in oestrogen receptor-positive (ER+) tumours is associated with worse survival. PgR status is usually defined as positive or negative using 1% positive nuclei as a cut-off point. In this study, we aimed to assess the clinicopathologic characteristics of ER+/PgR-/HER2- tumours by comparing them with ER+/PgR+/HER2- tumours using a PgR cut-off point of 20% as a divisive criterion.

Methods: We analysed 1,522 patients with primary breast cancer who had undergone surgery at the Cancer Center of Fudan University between 2012 and 2014. Age, grade, tumour size, lymph node status and lymphovascular invasion were assessed. Multinomial logistic regression, linear regression and chi-square test models were applied to assess associations between ER, PR and clinical features.

Results: ER+/PgR-/HER2- tumours showed poorer clinicopathologic characteristics relative to ER+/PgR+/HER2- tumours using a PgR threshold of 20% instead of 1%. The clinicopathologic characteristics did not differ between tumours with purely negative PgR expression and tumours with a PgR percentage ranging from 1% to 19%. The prognostic significance of PR expression appeared more pronounced in patients under a high Ki-67 status than those under a low Ki-67 status.

Conclusions: Based on these findings, we propose the use of a novel threshold of 20% to define PgR status. Nevertheless, the impact of this new criterion on patient management and clinical treatment requires additional study.

No MeSH data available.


Related in: MedlinePlus

Good overall correlation was observed between ER and PgR expression with clinicopathologic variables among ER+/PgR+/HER2- (a-l) tumours.ER expression levels were positively correlated with age, whereas PgR expression levels were negatively correlated with age. ER and PgR expression levels were both negatively correlated with grade, size, LN status, Ki-67 and LVI.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4418610&req=5

pone.0125067.g003: Good overall correlation was observed between ER and PgR expression with clinicopathologic variables among ER+/PgR+/HER2- (a-l) tumours.ER expression levels were positively correlated with age, whereas PgR expression levels were negatively correlated with age. ER and PgR expression levels were both negatively correlated with grade, size, LN status, Ki-67 and LVI.

Mentions: In the ER+/PgR+/HER2- group, the ER percentage ranged from 10% to 100% (median, 88.5%), and the PgR percentage ranged from 20% to 100% (median, 69.1%); none of the tumours expressed ER in the range of 1% to 9%. In the ER+/PgR-/HER2- group, the ER percentage ranged from 1% to 100% (median, 71.8%), and the tumours of 22 patients expressed ER at levels <10%, whereas the PgR percentage ranged from 0% to 15% (median, 3.3%). The distributions of ER scores in two groups are displayed in Fig 2. Higher ER expression (ER ≥ 50%) was more common in the ER+/PgR+/HER2- group than the ER+/PgR-/HER2- group (P < 0.0001). An association between ER, PR expression and clinicopathologic variables was observed in ER+/PgR+/HER2- tumours (Fig 3). The expression levels of ER and PR were directly correlated with the favourability of the clinicopathologic characteristics in ER+/PgR+/HER2- tumours.


Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.

Li AQ, Zhou SL, Li M, Xu Y, Shui RH, Yu BH, Yang WT - PLoS ONE (2015)

Good overall correlation was observed between ER and PgR expression with clinicopathologic variables among ER+/PgR+/HER2- (a-l) tumours.ER expression levels were positively correlated with age, whereas PgR expression levels were negatively correlated with age. ER and PgR expression levels were both negatively correlated with grade, size, LN status, Ki-67 and LVI.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4418610&req=5

pone.0125067.g003: Good overall correlation was observed between ER and PgR expression with clinicopathologic variables among ER+/PgR+/HER2- (a-l) tumours.ER expression levels were positively correlated with age, whereas PgR expression levels were negatively correlated with age. ER and PgR expression levels were both negatively correlated with grade, size, LN status, Ki-67 and LVI.
Mentions: In the ER+/PgR+/HER2- group, the ER percentage ranged from 10% to 100% (median, 88.5%), and the PgR percentage ranged from 20% to 100% (median, 69.1%); none of the tumours expressed ER in the range of 1% to 9%. In the ER+/PgR-/HER2- group, the ER percentage ranged from 1% to 100% (median, 71.8%), and the tumours of 22 patients expressed ER at levels <10%, whereas the PgR percentage ranged from 0% to 15% (median, 3.3%). The distributions of ER scores in two groups are displayed in Fig 2. Higher ER expression (ER ≥ 50%) was more common in the ER+/PgR+/HER2- group than the ER+/PgR-/HER2- group (P < 0.0001). An association between ER, PR expression and clinicopathologic variables was observed in ER+/PgR+/HER2- tumours (Fig 3). The expression levels of ER and PR were directly correlated with the favourability of the clinicopathologic characteristics in ER+/PgR+/HER2- tumours.

Bottom Line: The prognostic significance of PR expression appeared more pronounced in patients under a high Ki-67 status than those under a low Ki-67 status.Based on these findings, we propose the use of a novel threshold of 20% to define PgR status.Nevertheless, the impact of this new criterion on patient management and clinical treatment requires additional study.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.

ABSTRACT

Purpose: A lack of progesterone receptor (PgR) expression in oestrogen receptor-positive (ER+) tumours is associated with worse survival. PgR status is usually defined as positive or negative using 1% positive nuclei as a cut-off point. In this study, we aimed to assess the clinicopathologic characteristics of ER+/PgR-/HER2- tumours by comparing them with ER+/PgR+/HER2- tumours using a PgR cut-off point of 20% as a divisive criterion.

Methods: We analysed 1,522 patients with primary breast cancer who had undergone surgery at the Cancer Center of Fudan University between 2012 and 2014. Age, grade, tumour size, lymph node status and lymphovascular invasion were assessed. Multinomial logistic regression, linear regression and chi-square test models were applied to assess associations between ER, PR and clinical features.

Results: ER+/PgR-/HER2- tumours showed poorer clinicopathologic characteristics relative to ER+/PgR+/HER2- tumours using a PgR threshold of 20% instead of 1%. The clinicopathologic characteristics did not differ between tumours with purely negative PgR expression and tumours with a PgR percentage ranging from 1% to 19%. The prognostic significance of PR expression appeared more pronounced in patients under a high Ki-67 status than those under a low Ki-67 status.

Conclusions: Based on these findings, we propose the use of a novel threshold of 20% to define PgR status. Nevertheless, the impact of this new criterion on patient management and clinical treatment requires additional study.

No MeSH data available.


Related in: MedlinePlus